We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tailored second-line therapy in asthmatic children with the Arg<sup>16</sup> genotype.
- Authors
LIPWORTH, Brian J.; BASU, Kaninika; DONALD, Helen P.; TAVENDALE, Roger; MACGREGOR, Donald F.; MACGREGOR, Simon A.; PALMER, Colin N. A.; MUKHOPADHYAY, Somnath
- Abstract
The Arg16 ß2 receptor genotype confers increased susceptibility to exacerbations in asthmatic children taking regular LABA (long-acting ß2 agonists). We therefore evaluated using montelukast as an alternative to salmeterol as tailored second-line asthma controller therapy in children expressing this susceptible genotype. A total of 62 persistent asthmatic children with the homozygous Arg16 genotype were randomized to receive salmeterol (50 µg, b.i.d.) or montelukast (5 or 10 mg, once daily) as an add-on to inhaled fluticasone for 1 year. School absences (the primary outcome) were reduced with montelukast compared with salmeterol {difference in score= -0.40 [95% CI (confidence interval), -0.22 to -0.58]; P=0.005}. Salbutamol use was also reduced with montelukast compared with salmeterol [difference in score= -0.47 (95% CI, -0.16 to -0.79); P<0.0001]. Greater improvements occurred in both symptom and quality of life scores with montelukast against salmeterol, whereas there was no difference in FEV1 (forced expiratory volume in 1 s). In conclusion, montelukast may be suitable as tailored second-line controller therapy instead of salmeterol in asthmatic children expressing the susceptible Arg16 genotype, a move towards a personalized medicine approach to management.
- Subjects
ASTHMA in children; ADRENERGIC receptors; DISEASE susceptibility; SALMETEROL; DISEASE exacerbation; MONTELUKAST; RANDOMIZED controlled trials
- Publication
Clinical Science, 2013, Vol 124, Issue 8, p521
- ISSN
0143-5221
- Publication type
Article
- DOI
10.1042/CS20120528